Using a screening tool to detect diabetic neuropathy early
Utilizing the Michigan Neuropathy Screening Instrument, Routine Nerve Conduction Study (NCS), and Nerve Ultrasound for Early Detection of Diabetic Neuropathy
This study is testing a new screening tool to see if it can better detect nerve damage in people who have just been diagnosed with type 2 diabetes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 33 Years to 65 Years |
| Sex | All |
| Sponsor | Sohag University Academic / other |
| Locations | 1 site (Sohag) |
| Trial ID | NCT06514846 on ClinicalTrials.gov |
What this trial studies
This study compares the diagnostic accuracy of the Michigan Neuropathy Screening Instrument (MNSI) with routine nerve conduction studies and ultrasound examinations of specific nerves in patients recently diagnosed with type 2 diabetes. The goal is to identify diabetic peripheral neuropathy more effectively in this population. Participants will undergo various assessments, including questionnaires and physical examinations, to evaluate their neuropathy status.
Who should consider this trial
Good fit: Ideal candidates are adults aged 30-55 who have been diagnosed with type 2 diabetes within the past year.
Not a fit: Patients with known conditions that cause neuropathy or those with a longer duration of diabetes may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection and management of diabetic neuropathy, potentially improving patient outcomes.
How similar studies have performed: Other studies have shown promise in using screening instruments for early detection of diabetic neuropathy, suggesting this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ü Age: 30-55 y ü Type of diabetes: Type 2 ü Duration of diabetes: Within 1Year of diagnosis of Type 2 diabetes mellitus according to World Health Organization 1999 criteria Exclusion Criteria: * Patients who had known conditions that could present with neuropathy such as hereditary sensory neuropathy, vitamin B12 or folate deficiency, paraneoplastic conditions, autoimmune diseases, uremia, hypothyroidism, and ethanol abuse.
Where this trial is running
Sohag
- Faculty of medecine Sohag university — Sohag, Egypt (Recruiting)
Study contacts
- Study coordinator: Reda Khalaf Allah Khalil, Resident
- Email: redakhalaf@med.sohag.edu.eg
- Phone: 0102 006 5913
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.